Berivan Karatekin Usta
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Berivan Karatekin Usta has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Ilker Kolbas
Department of Thoracic Surgery Istanbul Aydın University VM Medical Park Florya Hospital Istanbul Turkey
2 shared publications - Esra Ergün Alış
Department of Infectious Disease, Istanbul Aydin University Florya Medical Park Hospital, Istanbul 34295, Turkey
1 shared publication - Ilker Kolbas
Faculty of Medicine, Department of Thoracic Surgery, Istanbul Aydın University, VM Medical Park Florya Hospital, Istanbul, Turkey
1 shared publication Irfan Cicin
1 shared publication- Irfan Cicin
Department of Medical Oncology, Istinye University, Istanbul 34000, Turkey
1 shared publication Neslihan Köse
1 shared publication
Latest Publications
- Open Access
- 14 August 2026
- Published by Elsevier in JTO Clinical and Research Reports
Osimertinib Following Amivantamab-Lazertinib-Associated Pneumonitis in EGFR-Mutant Non-Small Cell Lung Cancer: A Two-Case Report
- 14 August 2026
- Published by Elsevier in JTO Clinical and Research Reports
Open AccessOsimertinib Following Amivantamab-Lazertinib-Associated Pneumonitis in EGFR-Mutant Non-Small Cell Lung Cancer: A Two-Case Report
- Open Access
- 9 August 2026
- Published by IntechOpen
Treatment of Early-Stage Lung Cancer
Chest X-ray, computed tomography (CT), and positron emission tomography–computed tomography are utilized for the staging of non-small cell lung cancer (NSCLC). In Stage I cancers, the maximum tumor diameter reaches up to 4 cm; specifically, Stage IA tumors measure up to 3 cm, whereas Stage IB tumors range between 3 and 4 cm. Stage II disease is defined by a tumor size between 4 and 5 cm or by involvement of ipsilateral peribronchial or hilar lymph nodes (Stage IIB). Stage IA tumors should undergo surgical resection, preferably via minimally invasive techniques. Lobectomy remains the standard approach; however, recent studies have also demonstrated favorable outcomes with sublobar resections. Stereotactic body radiotherapy serves as an effective alternative when surgery is contraindicated. For Stage IB–IIB disease, multimodal strategies combining surgery, chemotherapy, immunotherapy, and radiotherapy are employed. Accumulating evidence indicates that neoadjuvant therapy (e.g., nivolumab combined with chemotherapy for Stage IB and Stage II) optimizes surgical outcomes. Platinum-based doublet adjuvant chemotherapy (typically cisplatin plus vinorelbine) should be recommended for resected Stage IIB tumors and considered for resected Stage IIA tumors. Adjuvant pembrolizumab is indicated for Stage IB–IIIA disease following surgical resection and subsequent adjuvant platinum-based chemotherapy. Furthermore, osimertinib is indicated for resected Stage IB–IIIA NSCLC harboring actionable mutations, specifically epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 substitutions. Although definitive surveillance guidelines are lacking, most centers recommend surveillance CT scans every six months for the first two to three years following definitive treatment, followed by annual scans subsequently.
- 9 August 2026
- Published by IntechOpen
Open AccessTreatment of Early-Stage Lung Cancer
Chest X-ray, computed tomography (CT), and positron emission tomography–computed tomography are utilized for the staging of non-small cell lung cancer (NSCLC). In Stage I cancers, the maximum tumor diameter reaches up to 4 cm; specifically, Stage IA tumors measure up to 3 cm, whereas Stage IB tumors range between 3 and 4 cm. Stage II disease is defined by a tumor size between 4 and 5 cm or by involvement of ipsilateral peribronchial or hilar lymph nodes (Stage IIB). Stage IA tumors should undergo surgical resection, preferably via minimally invasive techniques. Lobectomy remains the standard approach; however, recent studies have also demonstrated favorable outcomes with sublobar resections. Stereotactic body radiotherapy serves as an effective alternative when surgery is contraindicated. For Stage IB–IIB disease, multimodal strategies combining surgery, chemotherapy, immunotherapy, and radiotherapy are employed. Accumulating evidence indicates that neoadjuvant therapy (e.g., nivolumab combined with chemotherapy for Stage IB and Stage II) optimizes surgical outcomes. Platinum-based doublet adjuvant chemotherapy (typically cisplatin plus vinorelbine) should be recommended for resected Stage IIB tumors and considered for resected Stage IIA tumors. Adjuvant pembrolizumab is indicated for Stage IB–IIIA disease following surgical resection and subsequent adjuvant platinum-based chemotherapy. Furthermore, osimertinib is indicated for resected Stage IB–IIIA NSCLC harboring actionable mutations, specifically epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 substitutions. Although definitive surveillance guidelines are lacking, most centers recommend surveillance CT scans every six months for the first two to three years following definitive treatment, followed by annual scans subsequently.
- Open Access
- 11 December 2025
- Published by IntechOpen
Empyema/Fibrothorax
Pleural infections are a common clinical condition in which hospitalization costs, mortality, and morbidity decrease when treated promptly. The treatment of empyema involves the elimination of the infection source by removing the infected material, facilitating lung expansion, and initiating appropriate antibiotherapy. There is no clear algorithm for the drainage of infected material; the first option may include tube thoracostomy and/or fibrinolytic agents, as well as early thoracoscopic or conventional surgical methods.
- 11 December 2025
- Published by IntechOpen
Open AccessEmpyema/Fibrothorax
Pleural infections are a common clinical condition in which hospitalization costs, mortality, and morbidity decrease when treated promptly. The treatment of empyema involves the elimination of the infection source by removing the infected material, facilitating lung expansion, and initiating appropriate antibiotherapy. There is no clear algorithm for the drainage of infected material; the first option may include tube thoracostomy and/or fibrinolytic agents, as well as early thoracoscopic or conventional surgical methods.
- Open Access
- 17 October 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (10) , 2532
Early Postoperative C-Reactive Protein Trajectories After Thoracic Surgery: A Retrospective Cohort Study
Background: Distinguishing expected postoperative inflammation from early infection remains challenging after thoracic surgery; serial C-reactive protein (CRP) is widely used to aid this differentiation. Methods: We conducted a single-centre retrospective cohort study of adults undergoing thoracic surgery (1 January 2022–31 December 2024). CRP was measured preoperatively and on postoperative days (POD) 1–5; trajectories were compared by surgical approach and extent of resection using repeated-measures ANOVA with Greenhouse–Geisser correction (α = 0.05). Results: Among 144 patients (VATS n = 79; open thoracotomy n = 65; extent: segmentectomy n = 25, lobectomy n = 96, bilobectomy n = 9, pneumonectomy n = 14), overall CRP rose from 26.6 ± 45.0 mg/L preoperatively to a POD2 peak of 200.9 ± 72.7 mg/L, then declined to 118.1 ± 70.7 mg/L by POD5. Thoracotomy showed higher peaks than VATS (POD2 216.1 ± 76.0 vs. 152.3 ± 29.9 mg/L; POD3 206.7 ± 88.7 vs. 159.8 ± 72.4 mg/L), but time × approach was not statistically significant (F = 1.042, p = 0.381; partial η2 = 0.115). The extent analysis showed the highest peaks with pneumonectomy (POD2 273.7 ± 46.3 mg/L) compared with bilobectomy (155.7 ± 11.0 mg/L) and lobectomy (VATS 132.1 ± 3.7, open 196.8 ± 85.3 mg/L); time × extent was not significant (F = 1.136, p = 0.384; partial η2 = 0.299). The overall effect of time did not reach significance (F = 1.127, p = 0.352; partial η2 = 0.124), reflecting variability. Patients with clinically diagnosed infections exhibited more prolonged CRP elevation, often >100 mg/L beyond POD4, whereas uncomplicated cases declined after the POD2 peak; these trends did not achieve statistical significance in this cohort. Conclusions: Early postoperative CRP in thoracic surgery typically peaks at 48–72 h and then falls. Higher peaks with open surgery and more extensive resection were observed but not statistically confirmed; persistence > 100 mg/L after POD3–4 may flag complications. Prospective studies are needed to validate thresholds and refine CRP-based surveillance pathways.
- 17 October 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (10) , 2532
Open AccessEarly Postoperative C-Reactive Protein Trajectories After Thoracic Surgery: A Retrospective Cohort Study
Background: Distinguishing expected postoperative inflammation from early infection remains challenging after thoracic surgery; serial C-reactive protein (CRP) is widely used to aid this differentiation. Methods: We conducted a single-centre retrospective cohort study of adults undergoing thoracic surgery (1 January 2022–31 December 2024). CRP was measured preoperatively and on postoperative days (POD) 1–5; trajectories were compared by surgical approach and extent of resection using repeated-measures ANOVA with Greenhouse–Geisser correction (α = 0.05). Results: Among 144 patients (VATS n = 79; open thoracotomy n = 65; extent: segmentectomy n = 25, lobectomy n = 96, bilobectomy n = 9, pneumonectomy n = 14), overall CRP rose from 26.6 ± 45.0 mg/L preoperatively to a POD2 peak of 200.9 ± 72.7 mg/L, then declined to 118.1 ± 70.7 mg/L by POD5. Thoracotomy showed higher peaks than VATS (POD2 216.1 ± 76.0 vs. 152.3 ± 29.9 mg/L; POD3 206.7 ± 88.7 vs. 159.8 ± 72.4 mg/L), but time × approach was not statistically significant (F = 1.042, p = 0.381; partial η2 = 0.115). The extent analysis showed the highest peaks with pneumonectomy (POD2 273.7 ± 46.3 mg/L) compared with bilobectomy (155.7 ± 11.0 mg/L) and lobectomy (VATS 132.1 ± 3.7, open 196.8 ± 85.3 mg/L); time × extent was not significant (F = 1.136, p = 0.384; partial η2 = 0.299). The overall effect of time did not reach significance (F = 1.127, p = 0.352; partial η2 = 0.124), reflecting variability. Patients with clinically diagnosed infections exhibited more prolonged CRP elevation, often >100 mg/L beyond POD4, whereas uncomplicated cases declined after the POD2 peak; these trends did not achieve statistical significance in this cohort. Conclusions: Early postoperative CRP in thoracic surgery typically peaks at 48–72 h and then falls. Higher peaks with open surgery and more extensive resection were observed but not statistically confirmed; persistence > 100 mg/L after POD3–4 may flag complications. Prospective studies are needed to validate thresholds and refine CRP-based surveillance pathways.